UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3575-3581

2017

Volltextzugriff (PDF)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

Cancers, 2021-09, Vol.13 (18), p.4716

2021

Volltextzugriff (PDF)

Immune Therapy in GI Malignancies: A Review

Journal of clinical oncology, 2015-06, Vol.33 (16), p.1745-1753

2015

Volltextzugriff (PDF)

Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer

European journal of cancer (1990), 2018-05, Vol.94, p.1-5

2018

Volltextzugriff (PDF)

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors

Cancer, 2019-08, Vol.125 (16), p.2837-2845

2019

Volltextzugriff (PDF)

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy

Immunotherapy, 2014-04, Vol.6 (4), p.459-475

2014

Volltextzugriff (PDF)

Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial

Journal of the National Comprehensive Cancer Network, 2019-04, Vol.17 (4), p.358-364

2019

Volltextzugriff (PDF)

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1 , BRCA2 , or PALB2

Journal of clinical oncology, 2021-08, Vol.39 (22), p.2497-2505

2021

Volltextzugriff (PDF)

Targeting BRCA and PALB2 in Pancreatic Cancer

Current treatment options in oncology, 2024-03, Vol.25 (3), p.346-363

2024

Volltextzugriff (PDF)

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

The lancet oncology, 2022-08, Vol.23 (8), p.1009-1020

2022

Volltextzugriff (PDF)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

British journal of cancer, 2020-02, Vol.122 (3), p.333-339

2020

Volltextzugriff (PDF)

PARP Inhibitors in Pancreatic Cancer

The cancer journal (Sudbury, Mass.), 2021-11, Vol.27 (6), p.465-475

2021

Volltextzugriff (PDF)

Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer

Clinical cancer research, 2021-07, Vol.27 (13), p.3540-3542

2021

Volltextzugriff (PDF)

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Molecular cancer therapeutics, 2024-10, Vol.23 (10), p.1378-1388

2024

Volltextzugriff (PDF)

Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes

Clinical gastroenterology and hepatology, 2022-09, Vol.20 (9), p.1997-2004.e7

2022

Volltextzugriff (PDF)

PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma

Hematology/oncology clinics of North America, 2022-10, Vol.36 (5), p.1019-1032

2022

Volltextzugriff (PDF)

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

JAMA oncology, 2019-07, Vol.5 (7), p.993

2019

Volltextzugriff (PDF)

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Clinical cancer research, 2023-12, Vol.29 (24), p.5207-5216

2023

Volltextzugriff (PDF)

Healthy, but Comatose

The American journal of medicine, 2011-04, Vol.124 (4), p.303-305

2011

Volltextzugriff (PDF)

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)

Annals of surgical oncology, 2022-09, Vol.29 (9), p.5375-5376

2022

Volltextzugriff (PDF)

Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer

Genetics in medicine, 2021-11, Vol.23 (11), p.2105-2113

2021

Volltextzugriff (PDF)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.716-e689

2022

Volltextzugriff (PDF)

A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis

Clinical cancer research, 2015-01, Vol.21 (1), p.68-76

2015

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(198)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(238)

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(113)
Humans
(93)
Female
(55)
Male
(52)
Oncology
(52)
Adult
(26)
Middle Aged
(24)
Child
(22)
Aged
(21)
Patients
(15)
Animals
(13)
Chemotherapy
(13)
Infectious Diseases
(13)
Mutation
(13)
Pancreatic Neoplasms - Drug Therapy
(13)
Physical Sciences
(13)
Adolescent
(12)
Pancreatic Cancer
(12)
Pharmacology & Pharmacy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

Immune Therapy in GI Malignancies: A Review

Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy

Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1 , BRCA2 , or PALB2

Targeting BRCA and PALB2 in Pancreatic Cancer

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

PARP Inhibitors in Pancreatic Cancer

Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes

PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Healthy, but Comatose

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)

Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers

Suchergebnisse filtern